Edition:
India

Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

3.57USD
13 Sep 2019
Change (% chg)

$-0.18 (-4.80%)
Prev Close
$3.75
Open
$3.78
Day's High
$3.78
Day's Low
$3.46
Volume
28,964
Avg. Vol
44,628
52-wk High
$7.59
52-wk Low
$2.92

Latest Key Developments (Source: Significant Developments)

Cerecor Receives Fast Track Designation From FDA For Cerc-802
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - Cerecor Inc ::CERECOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR CERC-802 FOR THE TREATMENT OF MANNOSE-PHOSPHATE ISOMERASE DEFICIENCY.  Full Article

Cerecor Sees FY 2019 Revenue $20 Mln To $22 Mln
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Cerecor Inc ::CERECOR REPORTS SECOND QUARTER 2019 RESULTS.SEES FY 2019 REVENUE $20 MILLION TO $22 MILLION.QTRLY NET PRODUCT REVENUE DECREASED $0.3 MILLION TO $4.4 MILLION.QTRLY LOSS PER SHARE $0.11.Q2 EARNINGS PER SHARE VIEW $-0.15, REVENUE VIEW $5.3 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $21.1 MILLION -- REFINITIV IBES DATA.  Full Article

Cerecor Inc - Files For Offering Shares Of Common Stock, Size Not Disclosed - SEC Filing
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Cerecor Inc ::CERECOR INC - FILES FOR OFFERING SHARES OF COMMON STOCK, SIZE NOT DISCLOSED - SEC FILING.  Full Article

Cerecor Receives Fast Track Designation from FDA for CERC-801 For The Treatment Of PGM1 Deficiency
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Cerecor Inc ::CERECOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR CERC-801 FOR THE TREATMENT OF PGM1 DEFICIENCY.  Full Article

FDA Accepts IND Application For Cerecor’S Investigational Drug For The Treatment Of PGM1 Deficiency
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Cerecor Inc ::FDA ACCEPTS IND APPLICATION FOR CERECOR’S INVESTIGATIONAL DRUG CERC-801 FOR THE TREATMENT OF PGM1 DEFICIENCY.CERECOR INC - FDA HAS ACCEPTED ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CERC-801.  Full Article

Cerecor Q4 Loss Per Share $0.11
Monday, 2 Apr 2018 

April 2 (Reuters) - Cerecor Inc ::REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017.Q4 LOSS PER SHARE $0.11.SEES FY 2018 REVENUE MORE THAN $15 MILLION.Q4 REVENUE $2.2 MILLION.  Full Article

Cerecor Inc Appoints Peter Greenleaf CEO
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Cerecor Inc ::CERECOR APPOINTS PETER GREENLEAF AS CHIEF EXECUTIVE OFFICER.CERECOR - GREENLEAF MOST RECENTLY SERVED AS CHAIRMAN AND CEO OF SUCAMPO PHARMACEUTICALS.  Full Article

Cerecor To Acquire Avadel Pharmaceuticals' Pediatric Assets
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Cerecor Inc ::CERECOR TO ACQUIRE AVADEL PHARMACEUTICALS' PEDIATRIC ASSETS.TRANSACTION IS IMMEDIATELY ACCRETIVE TO REVENUE AND EARNINGS.WILL BUY AVADEL'S INTEREST IN AVADEL PEDIATRIC ASSETS FOR NOMINAL CASH PAYMENT.AVADEL IRELAND TO DEVELOP,PROVIDE CO WITH 4 STABLE PRODUCT FORMULATIONS OF CO'S CHOOSING UTILIZING PROPRIETARY LIQUITIME,MICROPUMP TECHNOLOGY.  Full Article

Cerecor announces leadership changes
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Cerecor Inc :Cerecor announces leadership changes.Cerecor Inc - ‍Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down​.Cerecor Inc - ‍Appoints Randal O. Jones and Robert C. Moscato, Jr. to board of directors​.Cerecor Inc - ‍ Names Robert Moscato as president and Chief Operating Officer​.Cerecor Inc - ‍Mariam Morris will continue as Cerecor's chief financial officer​.  Full Article

Cerecor reports Q3 earnings per share of $0.52
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cerecor Inc ::Cerecor Inc reports third quarter 2017 financial results.Q3 earnings per share $0.52.As of Sept 30, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million​.Expect existing cash and cash equivalents, initial proceeds from Janssen sale will fund operating expenditures through at least 2018​.  Full Article